LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Slēgts

SektorsVeselības aprūpe

0.66 3.13

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.63

Max

0.73

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-1.2M

Pārdošana

141K

21M

Peļņas marža

-5.978

Darbinieki

330

EBITDA

42K

197K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+203.03% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

321K

26M

Iepriekšējā atvēršanas cena

-2.47

Iepriekšējā slēgšanas cena

0.66

Ziņu noskaņojums

By Acuity

50%

50%

185 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Harvard Bioscience Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. nov. 18:59 UTC

Galvenie tirgus virzītāji

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

2025. g. 17. nov. 23:40 UTC

Tirgus saruna

Gold Consolidates Amid Mixed Signals -- Market Talk

2025. g. 17. nov. 23:34 UTC

Tirgus saruna

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025. g. 17. nov. 22:58 UTC

Tirgus saruna

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

2025. g. 17. nov. 22:46 UTC

Tirgus saruna

Risk Assets Set to Have a Strong 2026 -- Market Talk

2025. g. 17. nov. 22:06 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Rev $2.6B >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q Adj EPS $3.87 >TCOM

2025. g. 17. nov. 22:02 UTC

Peļņas

Trip.com Group 3Q EPS $4.02 >TCOM

2025. g. 17. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Adj EPS 26c >JHX

2025. g. 17. nov. 21:40 UTC

Peļņas

James Hardie Industries 2Q Loss/Shr 10c >JHX

2025. g. 17. nov. 21:39 UTC

Peļņas

James Hardie Industries 2Q Sales $1.29B >JHX

2025. g. 17. nov. 21:38 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 21:38 UTC

Peļņas

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q EPS BRL2.47 >XP

2025. g. 17. nov. 21:10 UTC

Peļņas

XP Inc. 3Q Rev BRL4.67B >XP

2025. g. 17. nov. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

2025. g. 17. nov. 20:12 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. nov. 20:09 UTC

Tirgus saruna

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

2025. g. 17. nov. 19:29 UTC

Tirgus saruna

Gold Slide Continues to Start Week -- Market Talk

2025. g. 17. nov. 19:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

2025. g. 17. nov. 16:45 UTC

Iegādes, apvienošanās, pārņemšana

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

2025. g. 17. nov. 16:16 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

2025. g. 17. nov. 16:15 UTC

Peļņas

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

2025. g. 17. nov. 15:40 UTC

Iegādes, apvienošanās, pārņemšana

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

2025. g. 17. nov. 15:22 UTC

Iegādes, apvienošanās, pārņemšana

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

2025. g. 17. nov. 15:19 UTC

Tirgus saruna

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Salīdzinājums

Cenas izmaiņa

Harvard Bioscience Inc Prognoze

Cenas mērķis

By TipRanks

203.03% augšup

Prognoze 12 mēnešiem

Vidējais 2 USD  203.03%

Augstākais 2 USD

Zemākais 2 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harvard Bioscience Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.3 / 0.3401Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

No Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

185 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat